ABSTRACT

Background

In patients with multiple sclerosis (MS), the suboptimal response should be well evaluated at every step of treatment.

Review Summary

Determining patients with moderate or high activity and suboptimal response to treatment (clinical variables, MRI activity, perception of the patient and physician, side effects, serious risks, etc.) and timely intervention in the treatment are very important in achieving the desired effectiveness in the long term. Within the early stages, there is a limited time interval for effective treatment of MS patients. During this time, intervention is critical to achieve long-term positive results. After diagnosis, an early and individualized specific treatment for MS, depending on the severity of the disease, can prevent radiological and physical disability in the medium/long term.

Conclusions

With the emergence of a number of new treatments each with their own benefits and risks, a change in the nature of interactions between patients and MS physicians has been anticipated and will be required in the patient-related clinical decision-making process in the developing MS landscape.

中文翻译：

---

决定多发性硬化治疗无效的因素

摘要

背景

在多发性硬化症 (MS) 患者中，应在治疗的每个步骤中充分评估次优反应。

评测总结

确定具有中度或高度活动且对治疗反应欠佳的患者（临床变量、MRI 活动、患者和医生的感知、副作用、严重风险等）并及时干预治疗对于在治疗中实现预期效果非常重要长期。在早期阶段，有效治疗 MS 患者的时间间隔有限。在此期间，干预对于取得长期积极成果至关重要。诊断后，根据疾病的严重程度对 MS 进行早期和个体化的特异性治疗，可以在中/长期预防放射和身体残疾。

结论

随着许多新疗法的出现，每种疗法都有其自身的益处和风险，预计患者和 MS 医生之间的互动性质会发生变化，这将需要在发展中的 MS 中与患者相关的临床决策过程中发生变化景观。